ENMD-2076 is our proprietary orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase and currently in multiple Phase 2 trials.
2ME2 (2-methoxyestradiol) is an orally active compound that has anti-proliferative, anti-angiogenic and anti-inflammatory properties.
MARQIBO, already marketed in the U.S. by our partner, is indicated for the treatment of advanced Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
EVOMELA (melphalan) for injection is intended to be used as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. EVOMELA was granted approval by the FDA of its New Drug Application in March 2016.
ZEVALIN, also already marketed in the U.S. by our partner, is indicated for patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL).
We intend to develop these drugs for import drug registration in our greater China region. For the most up-to-date safety information about these drugs, please refer to our partner’s website www.sppirx.com and to: